The company has several transdermal products in clinical trials in the us, including an insulin patch providing basal levels of the hormone for diabetes treatment, an apomorphine hydrochloride patch for management of advanced parkinsons disease, and a fentanyl citrate patch for moderate to severe pain management. Altea therapeutics announces positive clinical results from phase 1 human clinical studies for its basal insulin transdermal patch showing efficient. Treatment for certain diabetes cases involves constant monitoring of bloodglucose levels and daily insulin shots. Insulin injections may soon be a thing of the past by. Transdermal insulins altea has developed trandermal patches for insulin delivery. The team put their new smart patch to work on animal models of type 1 diabetes. Insulin patch how the insulin patch works, challenges. Listing a study does not mean it has been evaluated by the u. They found that mice wearing the patch had skyrocketing blood sugar levels significantly lowered for 10 hours at a time.
The entire system could be made to be worn like a pager electrically connected to. The smart insulin patch, developed by researchers in the joint uncnc state biomedical engineering department. Unlike most patch pumps current or in development, the vgo has no controller device that must be carried around and used to give commands. If insulin patches can be successfully developed, it would present the.
Needle free insulin infusion with thermal microporation. Traditional insulin pumps and software have received broad acceptance because of their ease of use, accuracy, predictability, and ability to calculate bolus insulin doses based on userinput information. Altea therapeutics completes phase 2 clinical study in. The answer may be an insulin patch in preclinical testing at altea development corporation. First, by a device that would make microscopic holes in the top layer of the skin and secondly, the application of patch over the skin. Altea therapeutics is an emerging private pharmaceutical company focused on developing and commercializing a broad portfolio of pharmaceutical products based on a new class of advanced transdermal. Altea therapeutics develops an insulin patch and ypsomed produces self. The patch most of the other forms of insulin in development are fastacting, so your mealtime dose would be covered. Altea therapeutics announced today that it has entered into an agreement with eli lilly and company and amylin pharmaceuticals, inc. Altea therapeutics has achieved sustained and steady basal levels of insulin in patients with type 1 diabetes using a small transdermal patch deliveri. Top insulin patch companies top ranked companies for keyword search. Atlantabusiness wirejuly 2, 2008 altea therapeutics announced today that it has entered into a partnership with hospira, inc. Altea therapeutics announces positive clinical results for. Alteas skin patches set to spread transdermal drug delivery.
Smart insulin patch for diabetes is years from human trials. It offers passport patch, a skin patch that uses short bursts of focused thermal energy to create tiny channels in the surface of the skin and these channels permit the flow of proteins, peptides, carbohydrates, and small molecules into the body without the use of needles. Insulin treatment insulinpeptide harmone produced by. The altea therapeutics passport system was the first product in development shown in us fda clinical trials to provide a noninvasive, controllable and. Smart insulin patch could replace painful injections for. Altea therapeutics and kai pharmaceuticals enter into a.
Transdermal basal insulin patch study in type 1 diabetes the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. The ultimate goal is the development of a needlefree, cost effective insulin infusion system. Gu says, is to develop a smart insulin patch that patients would only have to change every few days. This new insulin patch could soon replace injections for. Altea therapeutics is also in clinical development of a transdermal basal insulin patch for diabetes and a transdermal fentanyl citrate patch for pain. The vgo is a simpletouse, insulin delivery device that provides a preset basal rate and ondemand bolus dosing. Additional information about altea therapeutics may be found at about kai pharmaceuticals. First you would use a device that would make microscopic holes in the top layer of your skin. Valeritas is a medical technology company committed to the development and commercialization of innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Phase i efforts demonstrated the feasibility of an insulin infusion system which combines the thermal microporation method with iontophoresis. The electronic adhesive patch is first applied to the skin, vaporizing superficial dermal cells and forming micropores for insulin to pass through, and then insulin patch is applied.
Noninvasive transdermal insulin delivery could provide diabetic patients with sustained physiological levels of basal insulin in a painfree manner 64. Phase ii efforts will focus on patch design and insulin formulation to optimize the product as well as evaluating the capabilities, repeatability and controllability of a microportmbased insulin. With our investigation you gain business information with individual sales predictions and discussions. Their development and future in closedloop systems henry anhalt, d. The skin patch involves a twostep process, according to alan smith, ph. Altea development corporation is planning to introduce a product which will either be a one or halfday patch, depending on the outcome of. Last month, jdrf and sanofi announced a new research partnership in order to bring more funding for better research for better insulins and insulin delivery mechanisms for those living with type 1 diabetes. Discovery of insulin is appropriately attributed to banting and best. People with diabetes can still bring medical syringes and insulin with them onto aircraft despite new security restrictions introduced as a result of recent tragic events in the usa. In a glucoseclamp study in normal subjects, altea therapeutics achieved constant insulin delivery at therapeutic levels over a 12hour patch application period.
New security measures prohibit scissors, razors, nail clippers, knives or needles but they will allow medical syringes, lancets and insulin. An insulin patch aims to painlessly deliver insulin through the skin similar to how transdermal patches such as nicotine patches or muscle pain relief patches work. Transdermal basal insulin patch study in type 1 diabetes. Insulin patches are currently an experimental form of insulin delivery that are at an early stage of research.
Toward a smart patch that automatically delivers insulin. Altea therapeutics corporation develops and commercializes transdermal drug delivery systems. Altea therapeutics is an emerging specialty pharmaceutical company developing and commercializing products based on a new transdermal patch technology that can deliver therapeutic levels of watersoluble small drugs, therapeutic. The skin patch from altea development corporation involves a twostep process. But scientists are now developing a painless smart patch that monitors blood. Because mice are less sensitive to insulin than humans, the researchers think that the blood sugarstabilizing effects of the patch could last even longer when given to actual patients. The patch, which uses alteas micropore system, is being developed to deliver insulin for continuous basal the basic level of insulin a person needs throughout the day dosing. Insulin is secreted by groups of cells within the pancreas called islet cells. Patches are the examples to deliver basal insulin rather than fastacting boli in two steps process. A smart insulin patch that could potentially dispel the need for painful insulin injections for millions of people worldwide with diabetes has been developed by a team at the university of north. New york, ny prweb september 11, 2008 steven damon leads the business development team for altea therapeutics. A new smart patch lined with painless microneedles full of insulin has been developed by researchers in the us in an effort to do away with the uncomfortable injections that have become a part of life for the millions of type 1 diabetics around the world who need to manually regulate their hormone levels. First, an electronic adhesive patch, powered by a small battery, is applied to the skin.
1051 720 433 1181 553 1114 1146 1292 466 951 49 733 1250 654 332 1366 527 502 1408 1366 1305 207 437 907 481 351 940 1131 348 262 85 714 378 586 902 1103